OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Grisham on the Combination of VS-6766 With Defactinib in Ovarian Cancer

August 24th 2021

Rachel N. Grisham, MD, discusses the rationale to explore the combination of VS-6766 and defactinib in patients with low-grade serous ovarian cancer.

Dr. Slovin on Selecting Among Available Treatment Options in mCSPC

August 24th 2021

Susan F. Slovin, MD, PhD, discusses selecting among available treatment options for patients with metastatic castration-sensitive prostate cancer.

Dr. Van Tine on Outcomes With Catequentinib in Synovial Sarcoma

August 24th 2021

Brian A. Van Tine, MD, PhD, discusses outcomes with catequentinib in the treatment of patients with synovial sarcoma.

Dr. Fakih on Efficacy With Regorafenib Plus Nivolumab in Metastatic CRC

August 23rd 2021

Marwan Fakih, MD, discusses efficacy reported with regorafenib plus nivolumab in patients with mismatch repair–proficient and microsatellite stable metastatic colorectal cancer.

Dr. Stevenson on Ongoing Research Efforts in ES-SCLC

August 23rd 2021

James Stevenson, MD, discusses ongoing research efforts that are generating excitement in extensive-stage small cell lung cancer.

Dr. Shore on the Utility of PSMA PET Imaging Agent Piflufolastat F 18 for Prostate Cancer

August 23rd 2021

Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the clinical utility of piflufolastat F 18 in identifying suspected metastasis or recurrence of prostate cancer.

Dr. Litton on the Safety of Neoadjuvant Talazoparib in HER2-Negative Breast Cancer

August 23rd 2021

Jennifer Litton, MD, discusses the safety of talazoparib (Talzenna) in the neoadjuvant treatment of patients with germline BRCA1/2-positive, early-stage HER2-negative breast cancer.

Dr. Tagawa on the Integration of PSMA-Targeted Agents in Prostate Cancer

August 23rd 2021

Scott Tagawa, MD, MS, FACP, discuss the integration of targeted agents in prostate cancer.

Dr. Salem on the Utility of Y-90 Glass Microspheres in CRC

August 23rd 2021

Riad Salem, MD, discusses the history of TheraSphere™ Yttrium-90 in metastatic colorectal cancer.

Dr. Hammers on the Safety Profile of Lenvatinib/Pembrolizumab in RCC

August 20th 2021

Hans Hammers, MD, PhD,discusses the safety profile of lenvatinib in combination with pembrolizumab in renal cell carcinoma.

Dr. Funchain on the Rationale for the SWOG S1404 Trial in Melanoma

August 20th 2021

Pauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.

Dr. Vose on the Potential Utility of CAR T-Cell Therapy Across Non-Hodgkin Lymphoma

August 20th 2021

Julie M. Vose, MD, MBA, discusses the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma paradigm.

Dr. Spicer on Outcomes from the CheckMate-816 Trial in NSCLC

August 20th 2021

Jonathan Spicer, MD, PhD, discusses the efficacy observed with neoadjuvant nivolumab plus platinum-doublet chemotherapy in patients with resectable non–small cell lung cancer.

Dr. Willmott on Expanding Genomic Testing in Ovarian Cancer

August 19th 2021

Lyndsay Willmott, MD, discusses the expanding role for genomic testing in ovarian cancer.

Dr. Morris on Findings From the TheraP Study in mCRPC

August 19th 2021

Michael J. Morris, MD, discusses findings from the phase 2 TheraP study, and how they led to the development of the phase 3 VISION trial in metastatic castration-resistant prostate cancer.

Dr. Burgess on the Integration of PARP Inhibitors in Prostate Cancer

August 19th 2021

Earle Burgess, MD, discusses the integration of PARP inhibitors in advanced prostate cancer.

Dr. Monk on the Utility of PARP Inhibitors as Frontline Maintenance in Ovarian Cancer

August 19th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as frontline maintenance therapy in ovarian cancer.

Dr. Grisham on the Rationale for Binimetinib in Low-Grade Serous Ovarian Cancer

August 19th 2021

Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.

Dr. Kumar on the Future Directions With Pirtobrutinib in MCL

August 19th 2021

Anita Kumar, MD, discusses future directions with pirtobrutinib in mantle cell lymphoma.

Dr. Abida on Data from the PROfound Study in mCRPC

August 19th 2021

Wassim Abida, MD, PhD, discusses data from the phase 3 , PROfound trial in patients with metastatic castration-resistant prostate cancer.